Grifols, S.A.

Grifols is a global healthcare company that researches, develops, produces, and markets plasma-derived medicines. Its business is organized into four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment offers various hemoderivatives from human plasma for treating immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology conditions. The Diagnostic segment provides testing equipment, reagents, and services for transfusion medicine and clinical diagnostics. Bio Supplies supplies biological products like albumin, immunoglobulins, and thrombin to pharma and biotech companies. Additionally, Grifols offers healthcare solutions for hospitals, including intravenous solutions, clinical nutrition, and medical devices for interventional neuroradiology, hemodynamics, and cardiovascular surgery.

Grifols is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol GRFS. Its shares trade in US Dollars (USD). The company is headquartered in Spain and operates globally, but its US listing allows American investors to trade its stock easily. The choice of USD as the trading currency reflects its significant presence in the US market and facilitates investment from US-based shareholders.

Grifols operates in the Healthcare sector and is classified under the Drug Manufacturers - General industry. This means it is a pharmaceutical company that develops and manufactures a broad range of medications, specifically focusing on plasma-derived therapies. As a drug manufacturer, Grifols produces complex biologic drugs from human plasma, which are used to treat various serious medical conditions. Its industry classification highlights its role in producing essential medicines for hospitals and clinics worldwide.

Grifols is headquartered in Spain and serves markets globally. The company's description indicates it provides plasma-derived medicines worldwide, with a presence in regions including the US (as it is listed on Nasdaq). Its products are used in immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology. Grifols also offers diagnostic testing services and hospital solutions, including intravenous fluids, clinical nutrition, and medical devices. The company's global reach is supported by its manufacturing and research activities, which span multiple countries.

Grifols generates revenue through four main business segments. The Biopharma segment sells plasma-derived medicines such as albumin, immunoglobulins, and thrombin to treat a wide range of diseases. The Diagnostic segment markets testing equipment, reagents, and provides transfusion medicine and clinical diagnostic services. Bio Supplies sells biological products and intermediate plasma products to pharmaceutical and biotech companies for research and manufacturing. The Others segment includes hospital solutions like intravenous solutions, clinical nutrition, medical devices, and engineering services. Additionally, Grifols offers manufacturing services to third parties and engages in research activities. This diversified portfolio allows the company to earn income from both product sales and services across the healthcare value chain.